Skip to main content
OTCMKTS:HKMPY

Hikma Pharmaceuticals News Headlines

$67.89
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.89
$67.89
50-Day Range
$59.02
$67.89
52-Week Range
$55.86
$73.13
VolumeN/A
Average Volume2,162 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Hikma Pharmaceuticals (OTCMKTS HKMPY) News Headlines Today

SourceHeadline
Hikma Pharmaceuticals PLC -- Moodys withdraws Hikmas ratings for business reasonsHikma Pharmaceuticals PLC -- Moody's withdraws Hikma's ratings for business reasons
finance.yahoo.com - April 21 at 12:47 PM
What Is The Ownership Structure Like For Hikma Pharmaceuticals PLC (LON:HIK)?What Is The Ownership Structure Like For Hikma Pharmaceuticals PLC (LON:HIK)?
finance.yahoo.com - March 21 at 7:18 AM
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brothers Brother Foundation and the National Childrens Cancer SocietyHikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
finance.yahoo.com - February 18 at 12:44 PM
Heres Why I Think Hikma Pharmaceuticals (LON:HIK) Is An Interesting StockHere's Why I Think Hikma Pharmaceuticals (LON:HIK) Is An Interesting Stock
finance.yahoo.com - December 28 at 7:25 AM
Hikma launches generic Advair Diskus® following FDA approvalHikma launches generic Advair Diskus® following FDA approval
finance.yahoo.com - December 17 at 6:04 PM
MGE Energy Issues December 2020 Interim ReportMGE Energy Issues December 2020 'Interim Report'
finance.yahoo.com - December 15 at 1:17 PM
MGE Energy Issues Third-Quarter Financial UpdateMGE Energy Issues Third-Quarter Financial Update
finance.yahoo.com - November 6 at 5:06 PM
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicineHikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
feeds.benzinga.com - October 20 at 3:15 AM
Hikma Pharmaceuticals Plc ADR (HKMPY)Hikma Pharmaceuticals Plc ADR (HKMPY)
nasdaq.com - October 20 at 12:14 AM
Who Has Been Buying MGE Energy, Inc. (NASDAQ:MGEE) Shares?Who Has Been Buying MGE Energy, Inc. (NASDAQ:MGEE) Shares?
finance.yahoo.com - October 16 at 1:33 PM
We're Watching These Trends At MGE Energy (NASDAQ:MGEE)We're Watching These Trends At MGE Energy (NASDAQ:MGEE)
finance.yahoo.com - August 26 at 5:33 PM
Hikma Pharmaceuticals PLC's (LON:HIK) Business Is Trailing The Market But Its Shares Aren'tHikma Pharmaceuticals PLC's (LON:HIK) Business Is Trailing The Market But Its Shares Aren't
finance.yahoo.com - August 19 at 8:07 AM
Hikma Pharmaceuticals Regulatory NewsHikma Pharmaceuticals Regulatory News
lse.co.uk - August 9 at 7:11 AM
MGE Energy Reports Second-Quarter EarningsMGE Energy Reports Second-Quarter Earnings
finance.yahoo.com - August 6 at 1:22 PM
Hikma Pharmaceuticals PLC -- Moodys assigns Ba1 rating to Hikma Finance USA LLCs new notes; outlook stableHikma Pharmaceuticals PLC -- Moody's assigns Ba1 rating to Hikma Finance USA LLC's new notes; outlook stable
finance.yahoo.com - June 29 at 1:04 PM
Rigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in SessionRigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in Session
finance.yahoo.com - June 26 at 9:30 AM
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With Little Readthrough For Pending Patent AppealAmarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
finance.yahoo.com - June 17 at 5:00 PM
Hikma launches Dicyclomine Hydrochloride Oral SolutionHikma launches Dicyclomine Hydrochloride Oral Solution
finance.yahoo.com - May 28 at 9:42 AM
FDA Approves First Generic Version Of Vascepa; Amarin On WatchFDA Approves First Generic Version Of Vascepa; Amarin On Watch
markets.businessinsider.com - May 23 at 11:13 PM
Amarin Down 10% in Pre-Market On Generic ApprovalAmarin Down 10% in Pre-Market On Generic Approval
finance.yahoo.com - May 22 at 9:48 AM
Investors Who Bought Hikma Pharmaceuticals (LON:HIK) Shares A Year Ago Are Now Up 35%Investors Who Bought Hikma Pharmaceuticals (LON:HIK) Shares A Year Ago Are Now Up 35%
finance.yahoo.com - April 17 at 9:27 AM
Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For VascepaAmarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa
finance.yahoo.com - March 31 at 6:41 AM
Civica Rx and Hikma Announce Shipments of Heparin and Seven Other Essential Injectable MedicinesCivica Rx and Hikma Announce Shipments of Heparin and Seven Other Essential Injectable Medicines
finance.yahoo.com - December 10 at 7:56 AM
Hikma Ventures leads Series A financing for...Hikma Ventures leads Series A financing for...
www.benzinga.com - November 18 at 9:20 AM
Hikma Pharmaceuticals Plc ADR (Sponsored) (HKMPY) Revenue EPSHikma Pharmaceuticals Plc ADR (Sponsored) (HKMPY) Revenue EPS
www.nasdaq.com - November 6 at 12:47 PM
Hikma Pharmaceuticals (LON:HIK) Has A Rock Solid Balance SheetHikma Pharmaceuticals (LON:HIK) Has A Rock Solid Balance Sheet
finance.yahoo.com - October 15 at 8:42 AM
Hikma Pharmaceuticals PLC -- Moodys announces completion of a periodic review of ratings of Hikma Pharmaceuticals PLCHikma Pharmaceuticals PLC -- Moody's announces completion of a periodic review of ratings of Hikma Pharmaceuticals PLC
finance.yahoo.com - October 1 at 4:42 PM
Hikma launches prefilled syringes in the USHikma launches prefilled syringes in the US
finance.yahoo.com - September 26 at 10:16 PM
Hikma Pharma Launches New Prefilled Syringes In USHikma Pharma Launches New Prefilled Syringes In US
markets.businessinsider.com - September 17 at 10:21 AM
Hikma Pharma Agrees To Buy Certain Assets From Insys Therapeutics - Quick FactsHikma Pharma Agrees To Buy Certain Assets From Insys Therapeutics - Quick Facts
markets.businessinsider.com - August 9 at 10:26 AM
Hikma Pharma H1 Profit Climbs; Lifts FY19 Generics Revenue View - Quick FactsHikma Pharma H1 Profit Climbs; Lifts FY19 Generics Revenue View - Quick Facts
markets.businessinsider.com - August 9 at 10:26 AM
Hikma Ventures participates in $11 million funding round for Pillo HealthHikma Ventures participates in $11 million funding round for Pillo Health
finance.yahoo.com - May 30 at 4:54 PM
Hikma Pharmaceuticals PLC (LON:HIK): What’s The Analyst Consensus Outlook?Hikma Pharmaceuticals PLC (LON:HIK): What’s The Analyst Consensus Outlook?
finance.yahoo.com - March 15 at 11:17 AM
[$$] London Report: Drugmaker Hikma downgraded on competition fears[$$] London Report: Drugmaker Hikma downgraded on competition fears
finance.yahoo.com - January 8 at 4:44 PM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.